Inactive Instrument

Highlights DiaMedica Therapeutics Inc. Toronto S.E.

Equities

DMA

CA25253X2077

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

DiaMedica Therapeutics Launches Late-Stage Trial of Potential Stroke Treatment	Apr. 17	MT
DiaMedica Therapeutics Inc. Announces First Patient Dosed in Relaunch of Its Pivotal Phase /3 ReMEDy2 Trial of DM199 for the Treatment of Acute Ischemic Stroke	Apr. 17	CI
DiaMedica Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 19	CI
DiaMedica Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13	CI
Top Premarket Gainers	23-10-25	MT
DiaMedica Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
DiaMedica Therapeutics Announces US FDA's Removal of Clinical Hold on Phase 2/3 Trial for Ischemic Stroke Treatment DM199	23-06-21	MT
DiaMedica Therapeutics Inc. Announces That the FDA Has Removed the Clinical Hold on Dm199 Phase 2/3 Trial Forschemic Stroke	23-06-21	CI
Diamedica Therapeutics Inc. Files Complete Clinical Hold Response with the U.S. Food and Drug Administration Regarding the Status of the Remedy2 Study	23-05-22	CI
DiaMedica Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
DiaMedica Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-28	CI
DiaMedica Therapeutics Inc. Announces Update on Clinical Developments ReMEDy2 Phase 2/3 Trial	23-03-28	CI
DiaMedica Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-09	CI
DiaMedica Therapeutics Inc. Provides Update on Remedy2 Trial	22-10-26	CI
DiaMedica Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-10	CI
DiaMedica Therapeutics Says Phase 2/3 Trial of Stroke Drug Candidate on Clinical Hold; Stock Sinks 40% After Hours	22-07-06	MT
DiaMedica Therapeutics Announces Clinical Hold of its Phase 2/3 ReMEDy2 Clinical Trial for DM199	22-07-06	CI
DiaMedica Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-04	CI
DiaMedica Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	22-03-14	CI
DiaMedica Therapeutics Inc. Provides a Business Update	22-03-14	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights DiaMedica Therapeutics Inc. Toronto S.E.

Equities

DMA

CA25253X2077

Highlights

Filters